article · Frontiers in Immunology
Background Acute leukemia (AL) is a malignant hematological disorder, with two main subtypes: acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The incidence rate of AML and ALL is estimated at approximately 2.7 and 1.5 per 100,000 people, respectively, with an overall mortality rate of approximately 23.6%. This study aimed to investigate the association between human leukocyte antigen (HLA)-C genotypes and AML and ALL in a Moroccan population. Patients and methods A cross-sectional and comparative study was conducted on 100 patients with AL including 43 cases of AML and 57 cases of ALL, compared to 120 healthy individuals as controls. HLA-C genotyping was performed in the two groups, using the PCR-SSO (polymerase chain reaction–sequence-specific oligonucleotide)-based technique. Results The mean age of the patients was 32 ± 13 (2–62), with a sex ratio of 1.22 (55 male and 45 female patients). In patients with ALL categories, we observed a significantly higher frequency of HLA-C*12 [ p = 0.001; odds ratio (OR) = 7.58] allele groups. In the AML category, significant associations were observed between AML and the HLA-C*12 ( p = 0.0001; OR = 10.35) and HLA-C*08 ( p = 0.005; OR = 8.92) allele groups. Conclusion Our findings show a strong association between HLA-C*12 and HLA-C*08 allele groups and AL, including both ALL and AML, which gives evidence of a predisposing effect. This highlights the influence of HLA polymorphism in the occurrence or resistance of AL in our population.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3389/fimmu.2026.1869016
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.